Findings

What do systematic reviews say?

6 questions · 6 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 4 · 66.7%Moderate 2 · 33.3%High 0 · 0%

Formoterol vs short‐acting beta2‐agonist

Exacerbations needing hospitalisation · people with asthma

Formoterol showed no clear difference in patients with an exacerbation requiring hospitalisation compared with short‐acting beta2‐agonist (moderate certainty).

1 finding from 1 review

Formoterol versus short‐acting beta‐agonists as relief medication for adults and children with asthma 2010 · Cochrane Headline outcomes only
OR 0.84 [0.67, 1.04]
7 studies · 22236 participants
Moderate

Formoterol vs short‐acting beta2‐agonist

Exacerbations requiring oral corticosteroids ‐ adults · people with asthma

Formoterol probably leads to lower patients with an exacerbation requiring a course of oral… compared with short‐acting beta2‐agonist (moderate certainty).

1 finding from 1 review

Formoterol versus short‐acting beta‐agonists as relief medication for adults and children with asthma 2010 · Cochrane Headline outcomes only
OR 0.84 [0.77, 0.91]
6 studies · 21591 participants
Moderate

Formoterol vs short‐acting beta2‐agonist

Fatal serious adverse events · people with asthma

Formoterol showed no clear difference in fatal serious adverse events (all‐cause) compared with short‐acting beta2‐agonist (low certainty).

1 finding from 1 review

Formoterol versus short‐acting beta‐agonists as relief medication for adults and children with asthma 2010 · Cochrane Headline outcomes only
OR 1.08 [0.51, 2.3]
5 studies · 21629 participants
Low

Formoterol vs short‐acting beta2‐agonist

Patients with a serious adverse event (all cause) · people with asthma

Formoterol showed no clear difference in patients with a serious adverse event (all cause) compared with short‐acting beta2‐agonist (low certainty).

1 finding from 1 review

Formoterol versus short‐acting beta‐agonists as relief medication for adults and children with asthma 2010 · Cochrane Headline outcomes only
OR 0.94 [0.81, 1.08]
7 studies · 22538 participants
Low

Formoterol vs short‐acting beta2‐agonist

Asthma‐related serious adverse event · people with asthma

Formoterol showed no clear difference in patients with a serious adverse event (asthma related) compared with short‐acting beta2‐agonist (low certainty).

1 finding from 1 review

Formoterol versus short‐acting beta‐agonists as relief medication for adults and children with asthma 2010 · Cochrane Headline outcomes only
OR 0.91 [0.72, 1.15]
6 studies · 21986 participants
Low

Formoterol vs short‐acting beta2‐agonist

Withdrawals due to any reason · people with asthma

Formoterol may leads to higher withdrawals (any reason) compared with short‐acting beta2‐agonist (low certainty).

1 finding from 1 review

Formoterol versus short‐acting beta‐agonists as relief medication for adults and children with asthma 2010 · Cochrane Headline outcomes only
OR 1.12 [1.02, 1.24]
7 studies · 22541 participants
Low